Health-Related Quality of Life During Natalizumab Maintenance Therapy for Crohn's Disease

Feagan, Brian G.; Sandborn, William J.; Hass, Steven; Niecko, Timothy; White, Jeffrey
December 2007
American Journal of Gastroenterology;Dec2007, Vol. 102 Issue 12, p2737
Academic Journal
OBJECTIVES: We evaluated the effects of treatment on health-related quality of life (HRQoL) during a randomized controlled trial of natalizumab maintenance therapy (ENACT-2) using both disease-specific and generic measures. METHODS: Crohn's disease patients who received natalizumab as induction therapy in ENACT-1 (N = 724) and responded (N = 339) were re-randomized to ENACT-2 in which they received natalizumab 300 mg (N = 168) or placebo (N = 171) every 4 wk for 48 additional wk. Outcome measures were the change from baseline on the inflammatory bowel disease questionnaire (IBDQ), the short form-36 (SF-36), the EuroQol-5D (EQ-5D), and a subject global assessment. RESULTS: At entry into ENACT-1, scores indicated substantially impaired HRQoL for both the disease-specific and general measures. Natalizumab responders showed clinically meaningful improvement in HRQoL over the course of the ENACT-1 study. During maintenance therapy, IBDQ and SF-36 scale scores of patients who responded to natalizumab induction and were re-randomized to receive the drug in ENACT-2 (N = 168) remained stable, while those re-randomized to placebo (N = 171) worsened. At week 60, 48 wk after the initiation of maintenance therapy, the mean change from ENACT-1 baseline of all scales of the IBDQ and the SF-36 was significantly higher for those who continued to receive natalizumab ( P < 0.001 for all scales). The scores of patients who received maintenance natalizumab treatment were not statistically different from those of a cross-section of the U.S. population for 6 of 8 scales of the SF-36. CONCLUSIONS: The substantial improvement in HRQoL experienced by patients who responded to natalizumab induction therapy was maintained during an additional 48 wk of maintenance therapy.


Related Articles

  • Infliximab for Crohn's disease. ROSE, VERNA L. // American Family Physician;12/1/1998, Vol. 58 Issue 9, p2175 

    Introduces the monoclonal antibody, infliximab (Remicade), use for the treatment of Crohn's disease. Mechanism of action; Clinical trials; Side effects.

  • Research Brief: Crohn's disease.  // GP: General Practitioner;10/24/2012, p11 

    The article reports that researchers from the University of California, San Diego, have discovered that psoriasis drug, ustekinumab, may be useful in Crohn's disease.

  • Sarcoidosis complicating treatment with natalizumab for Crohn's disease. Parisinos, C. A.; Lees, C. W.; Wallace, W. A. H.; Satsangi, J. // Thorax;Dec2011, Vol. 66 Issue 12, p1109 

    Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had...

  • Medical Management of Crohn's Disease in 2006: What's on the Horizon? Lichtenstein, Gary R. // American Journal of Gastroenterology;Jun2007 Supplement, Vol. 102, pS2 

    The article focuses on the treatment approach for Crohn's disease. The monoclonal antibody therapy is found to be effective due to the achievement of adequate serological levels that allow patients to tolerate the biologic therapy without harmful effects. Part of such approach is the integration...

  • Remicade Approved for Children With Crohn's Disease.  // FDA Consumer;Jul/Aug2006, Vol. 40 Issue 4, p6 

    The article provides information on Remicade (infliximab), a drug approved by the U.S. Food and Drug Administration (FDA) to treat children with active Crohn's disease, a chronic inflammatory condition of the bowel that can be severely debilitating. Remicade is a genetically engineered...

  • Vedolizumab as induction and maintenance therapy for Crohn's disease/Vedolizumab as induction and maintenance therapy for ulcerative colitis.  // Inflammatory Bowel Disease Monitor;2014, Vol. 14 Issue 2, p55 

    Vedolizumab is a humanized immunoglobulin G mono-clonal antibody that targets the α4β7 integrin, thus inhibiting leukocyte adhesion and selectively reducing intestinal inflammation without enhancing opportunistic brain infections. These two articles report the results of the GEMINI 1...

  • Metabolic and crystal arthropathies. So, Alexander; De Meulemeester, M.; Pikhlak, A.; Yücel, A. E.; Bodalia, B.; Kerrane, J.; Arulmani, U.; Richard, D.; Stricker, K.; Ferreira, A.; Murphy, V.; Sallstig, P.; Schlesinger, N. // Rheumatology;Apr2011 Supplement 3, Vol. 50 Issue suppl_3, piii85 

    Background: Canakinumab, a fully human anti-IL-1β antibody has been shown to control inflammation in gouty arthritis. This study evaluated changes in health-related quality of life (HRQoL) in patients treated with canakinumab or triamcinolone acetonide (TA).Methods: An 8-wk, dose-ranging,...

  • Crohn's disease.  // Geriatrics;Dec98, Vol. 53 Issue 12, p16 

    Announces that Infliximab (Remicade), an intravenous (IV) injectable chimeric Immunoglobulin Gamma (IgG) monoclonal antibody, was approved for the treatment of Crohn's disease. Recommended dose; Most common side effects.

  • How do patients with inflammatory bowel disease want their biological therapy administered? Allen, Patrick B.; Lindsay, Hannah; Tham, Tony C. K. // BMC Gastroenterology;2010, Vol. 10, p1 

    Background: Infliximab is usually administered by two monthly intravenous (iv) infusions, therefore requiring visits to hospital. Adalimumab is administered by self subcutaneous (sc) injections every other week. Both of these anti-TNF drugs appear to be equally efficacious in the treatment of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics